Company intelligence / Profile preview

Suzhou RxD Biopharmaceutical Co., Ltd.

Suzhou, Jiangsu Sheng / Jiangsu Province, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Suzhou RxD Biopharmaceutical’s lead asset is recombinant human prourokinase targeting plasminogen for the treatment of ST Elevation Myocardial Infarction. This program has reached Phase 3 clinical development. Another asset, recombinant human brain natriuretic peptide, is also under development but its stage is not specified.[1]

Therapeutic areas: Cardiovascular
Modalities: Recombinant proteins/enzymes[1]
Industry: Biotech

Drug pipeline

1 asset

HC009

Phase 1

Indications: COVID-19

Beyond the preview

Go deeper on Suzhou RxD Biopharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou RxD Biopharmaceutical Co., Ltd..

Explore the full profile